CN113563311A - 用作雄激素受体拮抗剂的二芳基硫代乙内酰脲化合物 - Google Patents

用作雄激素受体拮抗剂的二芳基硫代乙内酰脲化合物 Download PDF

Info

Publication number
CN113563311A
CN113563311A CN202110901351.XA CN202110901351A CN113563311A CN 113563311 A CN113563311 A CN 113563311A CN 202110901351 A CN202110901351 A CN 202110901351A CN 113563311 A CN113563311 A CN 113563311A
Authority
CN
China
Prior art keywords
compound
alkyl
hydroxy
independently selected
synthesis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202110901351.XA
Other languages
English (en)
Chinese (zh)
Inventor
沈春莉
吴成德
陈胜林
陈曙辉
张喜全
田心
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Publication of CN113563311A publication Critical patent/CN113563311A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN202110901351.XA 2017-08-07 2018-08-07 用作雄激素受体拮抗剂的二芳基硫代乙内酰脲化合物 Pending CN113563311A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2017106678604 2017-08-07
CN201710667860 2017-08-07
CN201810333652 2018-04-13
CN2018103336525 2018-04-13
CN201880055633.9A CN111032644B (zh) 2017-08-07 2018-08-07 用作雄激素受体拮抗剂的二芳基硫代乙内酰脲化合物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201880055633.9A Division CN111032644B (zh) 2017-08-07 2018-08-07 用作雄激素受体拮抗剂的二芳基硫代乙内酰脲化合物

Publications (1)

Publication Number Publication Date
CN113563311A true CN113563311A (zh) 2021-10-29

Family

ID=65270909

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202110901351.XA Pending CN113563311A (zh) 2017-08-07 2018-08-07 用作雄激素受体拮抗剂的二芳基硫代乙内酰脲化合物
CN202110900404.6A Active CN113582977B (zh) 2017-08-07 2018-08-07 用作雄激素受体拮抗剂的二芳基硫代乙内酰脲化合物
CN201880055633.9A Active CN111032644B (zh) 2017-08-07 2018-08-07 用作雄激素受体拮抗剂的二芳基硫代乙内酰脲化合物

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202110900404.6A Active CN113582977B (zh) 2017-08-07 2018-08-07 用作雄激素受体拮抗剂的二芳基硫代乙内酰脲化合物
CN201880055633.9A Active CN111032644B (zh) 2017-08-07 2018-08-07 用作雄激素受体拮抗剂的二芳基硫代乙内酰脲化合物

Country Status (8)

Country Link
US (2) US11332465B2 (https=)
EP (1) EP3666772A4 (https=)
JP (1) JP7285838B2 (https=)
KR (1) KR102658095B1 (https=)
CN (3) CN113563311A (https=)
AU (1) AU2018314980B2 (https=)
CA (1) CA3072269A1 (https=)
WO (1) WO2019029521A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115724759A (zh) * 2022-11-23 2023-03-03 爱斯特（成都）生物制药股份有限公司 一种恩扎卢胺中间体的制备方法
CN116444444A (zh) * 2023-03-27 2023-07-18 盐城工业职业技术学院 一种制备2-取代喹唑啉酮类化合物的方法

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3666772A4 (en) 2017-08-07 2021-01-20 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. DIARYLTHIOHYDANTOIN COMPOUND AS ANDROGEN RECEPTOR ANTAGONIST
CN109422737B (zh) * 2017-08-22 2021-07-30 上海时莱生物技术有限公司 咪唑酮类雄激素受体拮抗剂、其制备方法和用途
BR112021015122A2 (pt) * 2019-02-01 2021-09-28 Chia Tai Tianqing Pharmaceutical Group Co., Ltd Cristal de composto de diariltio-hidantoína
CN110452166A (zh) * 2019-09-06 2019-11-15 浙江朗华制药有限公司 一种5-异硫氰酰基-3-三氟甲基-2-氰基吡啶的制备方法
CN114929702B (zh) * 2020-01-19 2024-05-31 正大天晴药业集团股份有限公司 作为ar拮抗剂的二芳基硫代乙内酰脲化合物
CN120112517A (zh) * 2022-10-28 2025-06-06 南京明德新药研发有限公司 桥环类化合物及其在药学上的应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2656842T (lt) * 2006-03-27 2016-09-26 The Regents Of The University Of California Androgeno receptoriaus moduliatorius, skirtas prostatos vėžio ir su androgeno receptoriumi susijusių ligų gydymui
CN101817787B (zh) * 2009-02-26 2013-07-24 童友之 抗前列腺癌的雄性激素受体拮抗剂
WO2011103202A2 (en) 2010-02-16 2011-08-25 Aragon Pharmaceuticals, Inc. Androgen receptor modulators and uses thereof
WO2013084138A1 (en) 2011-12-05 2013-06-13 Novartis Ag Cyclic urea derivatives as androgen receptor antagonists
CN103804358B (zh) 2012-11-14 2016-06-29 上海医药集团股份有限公司 一类二芳基乙内酰脲衍生物、其制备方法、药物组合物和应用
WO2015018356A1 (zh) 2013-08-08 2015-02-12 上海医药集团股份有限公司 二芳基乙内酰脲衍生物、其制备方法、药物组合物和应用
CN104341352A (zh) * 2013-08-09 2015-02-11 南京衡杰生物科技有限公司 作为雄激素受体拮抗剂的二芳基乙内酰脲化合物及其应用
CN104341342B (zh) 2014-10-23 2016-04-13 中国电子科技集团公司第四十六研究所 一种高产率、高纯度的dast源粉合成工艺
CN106146474A (zh) * 2015-04-24 2016-11-23 成都贝斯凯瑞生物科技有限公司 硫代咪唑二酮和咪唑二酮类化合物及其用途
TWI726969B (zh) * 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
CN110023297A (zh) 2016-07-08 2019-07-16 詹森药业有限公司 作为雄性激素受体拮抗剂的取代的乙内酰脲和硫代己内酰脲衍生物
RU2019108092A (ru) * 2016-08-22 2020-09-22 Янссен Фармацевтика Нв Тиогидантоиновые антагонисты андрогеновых рецепторов для лечения рака
EP3666772A4 (en) 2017-08-07 2021-01-20 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. DIARYLTHIOHYDANTOIN COMPOUND AS ANDROGEN RECEPTOR ANTAGONIST
CN109422737B (zh) * 2017-08-22 2021-07-30 上海时莱生物技术有限公司 咪唑酮类雄激素受体拮抗剂、其制备方法和用途
BR112021015122A2 (pt) 2019-02-01 2021-09-28 Chia Tai Tianqing Pharmaceutical Group Co., Ltd Cristal de composto de diariltio-hidantoína
CN114929702B (zh) * 2020-01-19 2024-05-31 正大天晴药业集团股份有限公司 作为ar拮抗剂的二芳基硫代乙内酰脲化合物

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115724759A (zh) * 2022-11-23 2023-03-03 爱斯特（成都）生物制药股份有限公司 一种恩扎卢胺中间体的制备方法
CN116444444A (zh) * 2023-03-27 2023-07-18 盐城工业职业技术学院 一种制备2-取代喹唑啉酮类化合物的方法

Also Published As

Publication number Publication date
EP3666772A1 (en) 2020-06-17
JP7285838B2 (ja) 2023-06-02
CN113582977A (zh) 2021-11-02
US11332465B2 (en) 2022-05-17
US20200277290A1 (en) 2020-09-03
CN111032644B (zh) 2021-08-10
KR102658095B1 (ko) 2024-04-19
KR20200043407A (ko) 2020-04-27
EP3666772A4 (en) 2021-01-20
JP2020530490A (ja) 2020-10-22
WO2019029521A1 (zh) 2019-02-14
CA3072269A1 (en) 2019-02-14
AU2018314980A1 (en) 2020-03-05
US11866433B2 (en) 2024-01-09
CN113582977B (zh) 2023-04-14
CN111032644A (zh) 2020-04-17
AU2018314980B2 (en) 2022-05-19
US20230035184A1 (en) 2023-02-02

Similar Documents

Publication Publication Date Title
CN113582977B (zh) 用作雄激素受体拮抗剂的二芳基硫代乙内酰脲化合物
CN103228653B (zh) 被取代的多环性氨基甲酰基吡啶酮衍生物的前药
CN113105475B (zh) 布鲁顿氏酪氨酸激酶的抑制剂及其使用方法
CN106459009B (zh) 丙肝病毒抑制剂及其制药用途
CN102448956B (zh) 丙型肝炎病毒抑制剂
CN113272301A (zh) 杂环类化合物、中间体、其制备方法及应用
CN114173803A (zh) 氨基酸化合物的剂型和方案
CN103249730A (zh) 丙型肝炎病毒抑制剂
TW201734021A (zh) 布魯頓氏（ｂｒｕｔｏｎ）酪胺酸激酶抑制劑及其使用方法
EP4423068B1 (en) Rxfp1 agonists
CN106164076A (zh) 作为ROS1抑制剂的被取代的4，5，6，7‑四氢‑吡唑并[1，5‑a]吡嗪衍生物和5，6，7，8‑四氢‑4H‑吡唑并[1，5‑a][1，4]二氮杂环庚三烯衍生物
WO2024153247A1 (zh) 作为ctps1抑制剂的化合物
HK40062758A (en) Diarylthiohydantoin compound as androgen receptor antagonist
HK40062758B (en) Diarylthiohydantoin compound as androgen receptor antagonist
HK40019862A (en) Diarylthiohydantoin compound as androgen receptor antagonist
HK40019862B (en) Diarylthiohydantoin compound as androgen receptor antagonist
RU2804108C9 (ru) Соединение диарилтиогидантоина в качестве антагониста андрогенового рецептора
RU2804108C1 (ru) Соединение диарилтиогидантоина в качестве антагониста андрогенового рецептора
WO2026046365A1 (zh) Smarca2抑制剂及其制备方法和用途
WO2025237304A1 (zh) 用于治疗和/或预防肝炎病毒感染的酰胺类化合物
WO2024208187A1 (zh) 氮杂芳基化合物及其作为lsd1抑制剂的用途
HK40048952A (en) Heterocyclic compound, intermediate, preparation method therefor and application thereof
HK40070149A (en) Dosage forms and regimens for amino acid compounds
TW201542521A (zh) 丙肝病毒抑制劑及其製藥用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination